Professor Derek Hart

Professor of Transplantation and Immunotherapy
ANZAC Research Institute, Concord Clinical School

Telephone +61 2 9767 9822

Map

Biographical details

Prof Hart has made major scientific and clinical contributions, particularly in relation to his special interest in dendritic cells (DC), immune therapies and bone marrow transplantation (BMT). He is a Rhodes Scholar and Royal College of Pathologists of Australasia Distinguished Fellow. Prof Hart discovered the interstitial DC during his postgraduate studies in Oxford and pioneered studies defining human DC and the role DC play in allogeneic transplantation. After returning to New Zealand and training as a clinical haematologist, Prof Hart became Director of the Christchurch Clinical Haematology Unit and BMT Unit and left it with a significant research reputation, including UK MRC trial participation. He completed 11 years as the inaugural Mater Medical Research Institute Director in Brisbane, establishing it as an internationally recognized institute with a strong translational program including clinical cell therapy trials. His leadership helped create the new Queensland Translational Institute. Prof Hart moved to the University of Sydney in 2010 to establish the DC Biology and Therapeutics Group at the ANZAC Research Institute and to undertake translational collaborative research projects at the Royal Prince Alfred, Westmead and Concord Hospitals. His human DC research program leads the field, including being the first to clone several white blood cell membrane (cluster of differentiation (CD)) antigens and define several human DC subsets. The Group continues to define DC cell surface antigens, including important immune regulator genes (CD300) and has several novel gene deleted mouse models under investigation. New preclinical humanized mouse models are being used to define other translational applications e.g. new DC targeted vaccines, a trial to predict acute graft versus host disease (AGVHD), novel anti - DC immune-suppressive agents and a new antibody for acute myeloid leukemia. His team’s novel immunosuppressive anti-CD83 technology is being developed commercially, by the CRC- Biomarker Translation, which he co-founded. Prof Hart has published 245 peer reviewed articles (95 in high impact or major specialty journals (e.g. 19 in Blood), with an H Factor of 47 and total citations of 10,806.Prof Hart is Chief Investigator on current NHMRC Program and Cancer Institute of New South Wales Translational Program Grants and holds or has held other Australian (NHMRC project, CRC-BT & other) grants and US/European grants, notably grants for DC immunotherapy (DOD, NIH) as well as philanthropic support. Prof Hart has licensed several patents and has used his intellectual property (IP) to attract commercial support from Pfizer, Miltenyi and Gambro. The IP from his group is managed and commercialized by DendroCyte BioTech. He has served on the NHMRC Academy and GRPs, chairs the Ramaciotti Foundation Scientific Advisory Board (SAB) and Institute of Glycomics SAB and serves on the Australian Bone Marrow Donor Registry Ethics Committee, Sydney Catalyst T1 Committee and Concord Cancer Centre Steering Committee. Prof Hart co-hosted the 6th International Symposium on Dendritic Cells (2000), is a member of the International Society for Cell Therapy Immunotherapy Committee and his Group is on the WHO/CD Committee and is hosting the International HLDA10 meeting in 2014. Prof Hart has been invited to speak at many national and international conferences. He and other members of his Group have received a number of prizes and awards. Prof Hart continues to host the popular “DC Down Under” annual DC scientific symposium and maintains interactions with a number of successful former students and postdoctoral fellows now in substantive positions in leading national and international institutions.

Research interests

The Dendritic Cell Biology and Therapeutics Group at the ANZAC Research Institute is a recently established research program focused on understanding dendritic cell biology to enable the development of new ways to treat haematological diseases. The group is a translational research group with projects suitable for PhD candidates interested in basic biology or more clinically focused work. Our main areas of focus are:

1. DC Antigen Discovery and Antibody Engineering

2. Dendritic Cell Biology: Fundamental and Applied

3. Immunostimulation/Cancer Vaccination

4. Immunosuppression/Anti-inflammatory

Teaching and supervision

Professor Hart specialises in postgraduate student supervision and works with his senior scientific colleagues in the Dendritic Cell Biology & Therapeutics Group (DCBTG) to provide a strong team based supervision of bench research. DCBTG has a strong translational program and provides an ideal environment for advanced clinical trainees. Postgraduate students also gain exposure to intellectual property commercialisation processes.

Current projects

  1. Discovering and defining the biology of novel DC surface molecules.
  2. Defining the function of the novel cell surface lectin DCL1 (CD302).
  3. Studies on the ability of the CD300 family of imunoregulatory molecules to control immune responses.
  4. The definition and functional characterization of novel human DC subsets.
  5. Studies on DC biology in allogeneic haematopoietic stem cell transplant patients.
  6. Studies on DC biology and the immune response in patients with multiple myeloma and other haematological malignancies aimed at developing immune therapies.
  7. The production of human monoclonal antibodies to CD83 as novel immunosuppressive agents, their evaluation in preclinical transplant models and testing in clinical trials.
  8. The production of novel antibodies to acute myeloid leukaemia for evaluation in clinical trial.
  9. The use of CMRF-56 immunoselected blood DC for therapeutic cancer vaccination.

Awards and honours

2012 & 2014 - John & Eileen Haddon Grant for Geriatric Research. 2012 - National Health and Medical Research Council Senior Principal Fellowship.2009 - Queensland Courier Mail “Fifty Best and Brightest Queenslanders”. 2009 - European Bone Marrow Transplant Meeting Basic Science Award (DC Program). 2008 - Queensland Courier Mail “Fifty Best and Brightest Queenslanders”. 2007 -Queensland Courier Mail “The A List; People who make us think”. 2006 - Royal College of Pathologists Distinguished Fellow for “Significant and ground breaking research in dendritic cells and other cell mediated therapies”. 2005 - Brisbane News - Living Legend. 2000 - TSANZ Australian Kidney Foundation Award, International Bone Marrow Transplant Registry Mortimer Bortin Award. 1997 - Rotary Paul Harris Fellow. 1996 - European Bone Marrow Transplant Meeting Award. 1987 - McCelland Fellowship. 1986 - Cancer Society of New Zealand Farmatalia Award. 1977 - Rhodes Scholarship. 1975 - Ardagh Memorial Prize, Senior Scholarship in Medicine. 1970 - Traveling Scholarship in Medicine. 1969 - University Scholarship.

Selected grants

2014

  • EVOS FL Auto cell imaging system; Nicholson G, Clark G, Zhou H, Jessup W, Le Couteur D, McMahon A, McLachlan A, Allan C, Handelsman D, Hart D, Walters K, Kritharides L, Kockx M, Kennerson M, Cooper M, Seibel M, Verma N, Silveira P, Fromm P, Simanainen U, Cogger V, Zheng Y; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • CyTOF Mass Cytometry Platform; Fazekas B, Weninger W, Richardson D, Halliday G, Gunning P, Hart D, Mann G, Goldys E, Jin D; Cancer Institute New South Wales/Equipment Grant.
  • Automacs Pro Seperator; Hart D, Handelsman D, Le Couteur D, Nicholson G, Kritharides L, Zhou H, Clark G, Kennerson M, Allan C, Walters K, Cogger V, Simanainen U, Zheng Y, Seibel M; DVC Research/Equipment Grant.
  • IVIS Lumina II in vivo Imaging System; Seibel M, Handelsman D, Le Couteur D, Hart D, Nicholson G, Freedman B, Kritharides L, Jessup W, Zhou H, Clark G, Kennerson M, Allan C, Walters K, Cogger V, McMahon A, Simanainen U, Kockx M, Speranza T, Zheng Y; DVC Research/Equipment Grant.

2012

  • BD Influx Cell Sorter; Hart D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Enabling Diagnostic and Therapeutic Antibodies for Haematological and other Malignancies; Hart D, Bradstock K, Joshua D; Cancer Institute New South Wales/Translational Program Grant.
  • Senior Principal Research Fellowship; Hart D; National Health and Medical Research Council (NHMRC)/Career Awards: Research Fellowships.

2011

  • The Translation of Dendritic Cell Biology into New Cancer Therapies; Hart D; Cancer Institute New South Wales/Career Development Fellowship.
  • MOLECULAR IMAGER CHEMIDoc XRS SYSTEM & MINI P ROTEAN GEL/TRANSBLOT Cell SYSTEM (BIO-RAD. AUSTRALIA; Allan C, Handelsman D, Zhou H, Seibel M, Kennerson M, Nicholson G, Blair I, Le Couteur D, McMahon A, Hart D, Clark G, Simanainen U; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2010

  • CRC - Biomarker Translation; Miszczak E, Hart D.
  • The Translation of Dendritic Cell Biology into Clinical Practice; Hart D, Bradstock K; National Health and Medical Research Council (NHMRC)/Program Grants.

2009

  • A Phase 1 Clinical Trial of a Human Chimeric Anti-Activated DC Antibody to Prevent AGVHD in high risk allo HSCT; Hart D, Bradstock K, Munster D; National Health and Medical Research Council (NHMRC)/Project Grants.
  • RNA loading of tumor associated antigens and the activation of blood dendritic cells fr oprostate cancer immunotherapy; Hart D; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Field, K., Vuckovic, S., Hart, D. (2005). Dendritic Cells. In Michael T. Lotze and Angus W. Thomson (Eds.), Measuring Immunity, (pp. 290-298). Elsevier.

Journals

  • Gasiorowski, R., Clark, G., Bradstock, K., Hart, D. (2014). Antibody therapy for acute myeloid leukaemia. British Journal of Haematology, 164(4), 481-495. [More Information]
  • Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, J., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia and Lymphoma, 55(5), 1090-1098. [More Information]
  • Hardy, M., Vari, F., Rossetti, T., Hart, D., Prue, R. (2013). A flow cytometry based assay for the enumeration of regulatory T cells in whole blood. Journal of Immunological Methods, 390(1-2), 121-126. [More Information]
  • Shahin, K., Sartor, M., Hart, D., Bradstock, K. (2013). Alterations in Chemokine Receptor CCR5 Expression on Blood Dendritic Cells Correlate With Acute Graft-Versus-Host Disease. Transplantation, 96(8), 753-762. [More Information]
  • Gasiorowski, R., Ju, X., Hart, D., Clark, G. (2013). CD300 molecule regulation of human dendritic cell functions. Immunology Letters, 149(1-2), 93-100. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]
  • Brown, R., Karieshma, K., Favaloro, J., Yang, S., Joy Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012). CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosis. Blood, 120(10), 2055-2063. [More Information]
  • Kassianos, A., Hardy, M., Ju, X., Vijayan, D., Ding, Y., Vulink, A., McDonald, K., Jongbloed, S., Wadley, R., Wells, C., Hart, D., et al (2012). Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli. European Journal of Immunology, 42(6), 1512-1522. [More Information]
  • Wilkinson, R., Woods, K., D'Rozario, R., Prue, R., Vari, F., Hardy, M., Dong, Y., Clements, J., Hart, D., Radford, K. (2012). Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology, Immunotherapy, 61(2), 169-179. [More Information]
  • Li, S., Roberts, S., Plebanski, M., Gouillou, M., Spelman, T., Latour, P., Jackson, D., Brown, L., Sparrow, R., Prince, H., Hart, D., et al (2012). Induction of Multi-Functional T Cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals. PLoS One, 7(8), 1-7. [More Information]
  • Fromm, P., Gottlieb, D., Bradstock, K., Hart, D. (2011). Cellular therapy to treat haematological and other malignancies: progress and pitfalls. Pathology, 43(6), 605-615. [More Information]
  • Freeman, L., Lam, A., Petcu, E., Smith, R., Salajegheh, A., Diamond, P., Zannettino, A., Evdikiou, A., Luff, J., Hart, D., et al (2011). Myeloma-induced alloreactive T cells arising in myeloma infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model. Journal of Immunology, 187(8), 3987-3996. [More Information]
  • Ding, Y., Ju, X., Azlan, M., Hart, D., Clark, G. (2011). Screening of the HLDA9 panel on peripheral blood dendritic cell populations. Immunology Letters, 134(2), 161-166. [More Information]
  • Hart, D. (2011). The delivery of effective therapeutic cancer vaccination. Asian Journal of Andrology, 13(2), 183-184. [More Information]
  • Jones, M., Seldon, T., Smede, M., Linville, A., Chin, D., Barnard, R., Mahler, S., Munster, D., Hart, D., Gray, P., et al (2010). A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. Journal of Immunological Methods, 354(1-Feb), 85-90. [More Information]
  • Gowans, E., Roberts, S., Jones, K., Dinatale, I., Latour, P., Chua, B., Eriksson, E., Chin, R., Li, S., Wall, D., et al (2010). A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. Journal of Hepatology, 53(4), 599-607. [More Information]
  • Jongbloed, S., Kassianos, A., McDonald, K., Clark, G., Ju, X., Angel, C., Chen, C., Dunbar, P., Wadley, R., jeet, V., Hart, D., et al (2010). Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. The Journal of Experimental Medicine, 207(6), 1247-1260. [More Information]
  • Kassianos, A., Jongbloed, S., Hart, D., Radford, K. (2010). Isolation of Human Blood DC Subtypes. Methods in Molecular Biology, 595(2010), 45-54. [More Information]
  • Dean, M., Flower, R., Eisen, D., Minchinton, R., Hart, D., Vuckovic, S. (2010). Mannose-binding lectin deficiency influences innate and antigen-presenting functions of blood myeloid dendritic cells. Immunology, 132(2), 296-305. [More Information]
  • Christensen, M., Turner, B., Sinfield, L., Kollar, K., Cullup, H., Waterhouse, N., Hart, D., Atkinson, K., Rice, A. (2010). Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease. Haematologica: the hematology journal, 95(12), 2102-2110. [More Information]
  • Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., Dalod, M., Grau, V., Hart, D., Leenen, P., Liu, Y., MacPherson, G., Randolph, G., et al (2010). Nomenclature of monocytes and dendritic cells in blood. Blood, 116(16), e74-e80. [More Information]
  • Ju, X., Clark, G., Hart, D. (2010). Review of human DC subtypes. Methods in Molecular Biology, 595, 3-20. [More Information]
  • Wilson, J., Cullup, H., Lourie, R., Sheng, Y., Palkova, A., Radford, K., Dickinson, A., Rice, A., Hart, D., Munster, D. (2009). Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. The Journal of Experimental Medicine, 206(2), 387-398. [More Information]
  • Hardy, M., Kassianos, A., Vulink, A., Wilkinson, R., Jongbloed, S., Hart, D., Radford, K. (2009). NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunology and Cell Biology, 87(8), 606-614. [More Information]
  • Clark, G., Ju, X., Tate, C., Hart, D. (2009). The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends in Immunology, 30(5), 209-217. [More Information]
  • Clark, G., Ju, X., Azlan, M., Tate, C., Ding, Y., Hart, D. (2009). The CD300 molecules regulate monocyte and dendritic cell functions. Immunobiology, 214, 730-736. [More Information]
  • Hart, D., Clark, G., Ju, X., Zenke, M. (2008). Cd300a and Cd300c on Plasmacytoid Dendritic Cells Are down-Regulated by Tlr7 and Tlr9 Ligand Induced Type I Interferon. Biology of Blood and Marrow Transplantation, 14(2), 118-118.
  • Ju, X., Zenke, M., Hart, D., Clark, G. (2008). CD300a/c regulate type I interferon and TNF-(alpha) secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood, 112, 1184-1194. [More Information]
  • Vuckovic, S., Wahid, F., Rice, A., Kato, M., Khalil, D., Rodwell, R., Hart, D. (2008). Compartmentalization of allogeneic T-cell responses in the bone marrow and spleen of humanized NOD/SCID mice containing activated human resident myeloid dendritic cells. Experimental Hematology, 36, 1496-1506. [More Information]
  • Vulink, A., Radford, K., Melief, C., Hart, D. (2008). Dendritic Cells in Cancer Immunotherapy. Advances in Cancer Research, 99, 363-407. [More Information]
  • Vari, F., Munster, D., Hsu, J., Rossetti, T., Mahler, S., Grey, P., Turtle, C., Prue, R., Hart, D. (2008). Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma. British Journal of Haematology, 143(3), 374-377. [More Information]
  • Turner, B., Kambouris, M., Sinfield, L., Lange, J., Burn, A., Lourie, R., Atkinson, K., Hart, D., Munster, D., Rice, A. (2008). Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem-Cell Transplant Determines the Kinetics of Acute Graft-Versus-Host Disease. Transplantation, 86(7), 968-976. [More Information]
  • Hart, D., Vuckovic, S., Alison, R., Kato, M., Khalil, D., Fadilah, S., Rodwell, R. (2008). Resident Human Myeloid Dendritic Cell Activation and Local Allogeneic T Cell Responses in the Bone Marrow of Humanized NOD/SCID Mice. Biology of Blood and Marrow Transplantation, 14(2), 145-145.
  • Liu, X., Hart, D., MacPherson, G., Good, M., Wykes, M. (2008). Soluble CD38 significantly prolongs the lifespan of memory B-cell responses. Immunology, 125, 14-20. [More Information]
  • Lau, J., Sartor, M., Bradstock, K., Vuckovic, S., Munster, D., Hart, D. (2007). Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease. Transplantation, 83(7), 839-846. [More Information]
  • Freeman, J., Vari, F., Hart, D. (2007). Activated CMRF-56 selected blood dendritic cells: A potential anti-myeloma vaccine. Blood, 110(11), 739a-740a.
  • Freeman, J., Vari, F., Hart, D. (2007). CMRF-56 immunoselected blood dendritic cell preparations activated with GM-CSF induce potent antimyeloma cytotoxic T-cell responses. Journal of Immunotherapy, 30(7), 740-748. [More Information]
  • Fadilah, S., Vuckovic, S., Khalil, D., Hart, D. (2007). Cord Blood CD34+ Cells Cultured with FLT3L, Stem Cell Factor, Interleukin-6, and IL-3 Produce CD11c+CD1a-/c Myeloid Dendritic Cells. Stem Cells and Development, 16, 849-855. [More Information]
  • Vuckovic, S., Withers, G., Harris, M., Khalil, D., Gardiner, D., Flesch, I., Tepes, S., Greer, R., Cowley, D., Cotterill, A., Hart, D. (2007). Decreased blood dendritic cell counts in type 1 diabetic children. Clinical Immunology, 123, 281-288. [More Information]
  • Young, J., Merad, M., Hart, D. (2007). Dendritic Cells in Transplantation and Immune-Based Therapies. Biology of Blood and Marrow Transplantation, 13(Supp. 1), 23-32. [More Information]
  • Clark, G., Jamriska, L., Rao, M., Hart, D. (2007). Monocytes immunoselected via the novel monocyte specific molecule, CD300e, differentiate into active migratory dendritic cells. Journal of Immunotherapy, 30(3), 303-311. [More Information]
  • Hart, D., Rao, M., Ju, X., Clark, G. (2007). Novel Human CD4+ T Lymphocyte Subpopulations Defined by CD300a/c Molecule Expression. Blood, 110(11), 682a-682a.
  • Clark, G., Rao, M., Ju, X., Hart, D. (2007). Novel human CD4+ T lymphocyte subpopulations defined by CD300a/c molecule expression. Journal of Leukocyte Biology, 82(5), 1126-1135. [More Information]
  • Hardy, M., Kassianos, A., Wilkinson, R., Vulink, A., Hart, D., Radford, K. (2007). Residual Lymphocytes in GM-CSF and IL-15 Differentiated Monocyte-Derived Dendritic Cells Enables Cytotoxic T Lymphocyte Responses. Blood, 110(11), 302b-302b.
  • Hart, D., Khan, S., d'Aniello, E., MacDonald, K., Kato, M. (2007). Role of Novel C-Type Lectin Receptor DCL-1 in Phagocytes and Dendritic Cells. Blood, 110(11), 713a-714a.
  • Kato, M., Khan, S., d’Aniello, E., McDonald, K., Hart, D. (2007). The Novel Endocytic and Phagocytic C-Type Lectin Receptor DCL-1/CD302 on Macrophages Is Colocalized with F-Actin, Suggesting a Role in Cell Adhesion and Migration. Journal of Immunology, 179, 6052-6063. [More Information]
  • Cullup, H., Wilson, J., Dickinson, A., Hart, D., Munster, D. (2006). Anti-CD83 mediated suppression of alloimmune responses. Immunology and Cell Biology, 84(3), A15-A6.
  • Hsu, A., Kerr, B., Lock, R., Hart, D., Rice, A. (2006). Anti-leukemic CTL generated by RNA loaded cord blood-derived dendritic cells control leukaemia in a NOD-SCID mouse model. Blood, 108(11), 1057a-1057a.
  • Cullup, H., Wilson, J., Rice, A., Dickinson, A., Munster, D., Hart, D. (2006). Antibody targeting of activated dendritic cells prevents AGVHD and preserves T cell immunity. Blood, 108(11), 925a-925a.
  • Radford, K., Turtle, C., Kassianos, A., Hart, D. (2006). CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression. Journal of Immunotherapy, 29(6), 596-605. [More Information]
  • Hart, D., Venter, D. (2006). Dendritic cells in leukemia and lymphoma. Leukemia and lymphoma, 47(4), 572-573. [More Information]
  • Lau, J., Sartor, M., Vuckovic, S., Munster, D., Bradstock, K., Hart, D. (2006). Expression of activation marker, CMRF-44, on blood CD11c(hi) dendritic cells is closely associated with the severity of acute gvhd after allogeneic haematopoietic stem cell transplant. Immunology and Cell Biology, 84(3), A9-A9.
  • Kato, M., McDonald, K., Khan, S., Ross, I., Vuckovic, S., Chen, K., Munster, D., MacDonald, K., Hart, D. (2006). Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. International Immunology, 18(6), 857-869. [More Information]
  • Khan, S., Hsu, R., Jones, A., Ross, I., Hart, D., Kato, M. (2006). IdentiWcation of the dominant translation start site in the attB1 sequence of the pET-DEST42 Gateway vector. Protein Expression and Purification, 49, 102-107. [More Information]
  • Wilson, J., Cullup, H., Rice, A., Hart, D., Munster, D. (2006). In vivo depletion of human activated dendritic cells prevents graft versus host disease in a human-mouse chimeric model. Experimental Hematology, 34(9), 44-44.
  • Modra, C., Jamriska, L., Rao, M., Clark, G., Hart, D. (2006). MMRI-23: A potential role in AML antibody-mediated therapy. Blood, 108(11), 225b-225b.
  • Wilkinson, R., Kassianos, A., Swindle, P., Hart, D., Radford, K. (2006). Numerical and Functional Assessment of Blood Dendritic Cells in Prostate Cancer Patients. The Prostate, 66, 180-192. [More Information]
  • Hsu, A., Kerr, B., Jones, K., Lock, R., Hart, D., Rice, A. (2006). RNA Loading of Leukemic Antigens into Cord Blood-Derived Dendritic Cells for Immunotherapy. Biology of Blood and Marrow Transplantation, 12, 855-867. [More Information]
  • Wahid, F., Rice, A., Khalil, D., Rodwell, R., Hart, D. (2006). Stem cells develop into human blood dendritic cells in humanized NOD/SCID mice. Cytometry Part A, 69A(5), 405-405.
  • Cooper, B., Key, B., Carter, A., Angel, N., Hart, D., Kato, M. (2006). Suppression and overexpression of adenosylhomocysteine hydrolase like protein 1 (AHCYL1) influences zebrafish embryo development - a possible role for AHCYL1 in inositol phospholipid signaling. Journal of Biological Chemistry, 281(11), 22471-22484. [More Information]
  • Collin, M., Hart, D., Jackson, G., Cook, G., Cavet, J., Mackinnon, S., Middleton, P., Dickinson, A. (2006). The fate of human Langerhans cells in hematopoietic stem cell transplantation. The Journal of Experimental Medicine, 203(1), 27-33. [More Information]
  • Wilson, J., Rice, A., Hart, D., Munster, D. (2005). A murine transplantation model of in vivo dendritic cell depletion to attenuate graft versus host disease. Biology of Blood and Marrow Transplantation, 11(2 supp. 1), 43-43.
  • Kato, M., Khan, S., McDonald, K., Hart, D. (2005). A novel C-type lectin receptor DCL-1 (CD302) is a potential endocytic receptor for tumor antigen loading into antigen presenting cells. Blood, 106(11), 628a-628a.
  • Modra, C., Radford, K., Gardiner, D., Hart, D., Clark, G. (2005). An inhibitory molecule involved in myeloid and DC differentiation. Tissue Antigens: immune response genetics, 66(5), 494-494.
  • Hsu, A., Kerr, B., Lock, R., Hart, D., Rice, A. (2005). Assembling the players for evaluation of anti-leukemic CTL activity in NOD-SCID mice. Blood, 106(11), 226b-226b.
  • Turner, B., Christensen, M., Lange, J., Burns, A., Hart, D., Atkinson, K., Munster, D., Rice, A. (2005). Conditioning Intensity and Dendritic Cell (DC) Activation: Implications for GVHD Control Using DC Depleting Antibodies. Blood, 106(11), 870a-870a.
  • Hart, D. (2005). Dendritic cell biology evolves into clinical application. The Lancet, 365(9454), 102-104. [More Information]
  • Clark, G., Munster, D., Yusuf, S., Hart, D. (2005). Eighth Leucocyte DiVerentiation Antigen Workshop DC section summary. Cellular Immunology, 236, 21-28. [More Information]
  • McKinlay, A., Radford, K., Gardiner, D., Khalil, D., Field, K., Burnell, F., Hart, D., Vuckovic, S. (2005). Human memory CD4(+) T cells maintained in the absence of antigen develop regulatory T cells capable of suppressing antibody responses. 66(5), 581-582.
  • Radford, K., Turtle, C., Kassianos, A., Vuckovic, S., Gardiner, D., Khalil, D., Taylor, K., Wright, S., Gill, D., Hart, D. (2005). Immunoselection of Functional CMRF-56+ Blood Dendritic Cells from Multiple Myeloma Patients for Immunotherapy. Journal of Immunotherapy, 28(4), 322-331. [More Information]
  • Collin, M., Munster, D., Clark, G., Wang, X., Dickinson, A., Hart, D. (2005). In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of Graft-versus-host disease. Transplantation, 79(6), 722-725. [More Information]
  • Dean, M., Minchinton, R., Vuckovic, S., Hart, D. (2005). Mannose binding lectin facilitates aggregation between cells of innate and adaptive immunity and pathogen recognition. Tissue Antigens: immune response genetics, 66(5), 396-396.
  • Wilson, J., Rice, A., Hart, D., Munster, D. (2005). Prevention of graft versus host disease by antibody mediated depletion of activated dendritic cells. Biology of Blood and Marrow Transplantation, 11(2), 43-43. [More Information]
  • Hardy, M., Kassianos, A., Clark, G., Hart, D., Radford, K. (2005). Production of IL-2, IL-12, and IL-10 by human blood myeloid dendritic cells. Tissue Antigens: immune response genetics, 66(5), 437-437.
  • Vuckovic, S., Khalil, D., Angel, N., Jahnsen, F., Hamilton, I., Boyce, A., Hock, B., Hart, D. (2005). The CMRF58 antibody recognizes a subset of CD123hi dendritic cells in allergen-challenged mucosa. Journal of Leukocyte Biology, 77(3), 344-351. [More Information]
  • Khan, S., Hsu, R., Hart, D., Kato, M. (2005). The use of the C type lectins DEC-205 (CD205) and DCLA (CD302) to load tumor-associated antigens into dendritic cells. Tissue and Cell, 66(5), 462-463.
  • Radford, K., Vari, F., Hart, D. (2005). Vaccine strategies to treat lymphoproliferative disorders. Pathology, 37(6), 534-550. [More Information]
  • Turtle, C., Brown, R., Joshua, D., Hart, D. (2004). DC in multiple myeloma immunotherapy. Cytotherapy, 6(2), 128-137.
  • A, R., Jones, K., Hart, D. (2004). DC preparations for therapy. Cytotherapy, 6(2), 99-104.
  • Turtle, C., Hart, D. (2004). Dendritic cells in tumor immunology and immunotherapy. Current Drug Targets, 5(1), 17-39.
  • Hsu, A., Kerr, B., Allan, C., Turtle, C., Hart, D., Rice, A. (2004). Effective RNA loading of CD34(+) derived dendritic cells for adoptive immunotherapy. Biology of Blood and Marrow Transplantation, 10(2), 47-47.
  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β�? In Patients With Myeloma. British Journal of Haematology, 125(2), 743-748.
  • Hart, D. (2004). In Focus - Introduction. Cytotherapy, 6(2), 87.
  • Sénéchal, B., Boruchov, A., Reagan, J., Hart, D., Young, J. (2004). Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood, 103(11), 4207-4215.
  • Vari, F., Hart, D. (2004). Loading DCs with Ag. Cytotherapy, 6(2), 111-121.
  • Vuckovic, S., Gardiner, D., Field, K., Chapman, G., Khalil, D., Gill, D., Marlton, P., Taylor, K., Wright, S., Pinzon-Charry, A., Hart, D., et al (2004). Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. Journal of Immunological Methods, 284, 73-87.
  • Turtle, C., Radford, K., Allan, C., Kassianos, A., Kato, M., Vuckovic, S., MacDonald, K., Lopez, J., Jackson, D., Wright, S., Hart, D., et al (2004). RNA-loading of CMRF-56 positive blood dendritic cells is a promising strategy for multiple myeloma immunotherapy. Biology of Blood and Marrow Transplantation, 10(2), 71-71.
  • Allan, C., Turtle, C., Mainwaring, P., Pyke, C., Hart, D. (2004). The immune response to breast cancer, and the case for DC immunotherapy. Cytotherapy, 6(2), 154-163.
  • Wilson, J., Rice, A., Hart, D., Munster, D. (2004). Therapeutic antibody mediated depletion of activated dendritic cells and the prevention of graft versus host disease. Biology of Blood and Marrow Transplantation, 10(2), 48-48.
  • Hart, D., Khan, S., McDonald, K., O’Neill, B., Gonzalez, N., Kato, M. (2003). A novel C-type lectin receptor DCL-1 is a potential Endocytic receptor expressed on phagocytes. Blood, 102(11), 523a-523a.
  • Koppi, T., Munster, D., Brown, L., MacDonald, K., Hart, D. (2003). CMRF-44 antibody-mediated depletion of activated human dendridic cells: a potential means for improving allograft survival. Transplantation, 75(10), 1723-1730.
  • Barrow, L., Brown, R., Murray, A., Sze, D., POPE, B., Gibson, J., Hart, D., Joshua, D. (2003). CMRF44+ Dendritic Cells from Peripheral Blood Stem Cell Harvests of Patients with Myeloma as Potential Cellular Vectors for Idiotype Vaccination. Leukemia and lymphoma, 44(12), 2117-2122.
  • MacDonald, K., Rowe, V., Filippich, C., Thomas, R., Clouston, A., Welpy, J., Hart, D., Ferrara, J., Hill, G. (2003). Donor pretreatment with progenipoietin-1 is superior to granulocyte colony–stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood, 101(5), 2033-2042.
  • Kato, M., Khan, S., Gonzalez, N., O’Neill, B., McDonald, K., Cooper, B., Angel, N., Hart, D. (2003). Hodgkin’s Lymphoma Cell Lines Express a Fusion Protein Encoded by Intergenically Spliced mRNA for the Multilectin Receptor DEC-205 (CD205) and a Novel C-type Lectin Receptor DCL-1*. Journal of Biological Chemistry, 278(36), 34035-34041.
  • Turtle, C., Radford, K., Allan, C., Kato, M., Hart, D. (2003). RNA-loading of CMRF-56 positive blood dendritic cells is a promising strategy for multiple myeloma immunotherapy. Blood, 102(11), 391b-391b.
  • Lopez, J., Bioley, G., Turtle, C., Pinzon-Charry, A., Ho, C., Vuckovic, S., Crosbie, G., Jackson, D., Gilleece, M., Munster, D., Hart, D. (2003). Single step enrichment of blood dendritic cells by positive immunoselection. Journal of Immunological Methods, 274, 47-61.

2014

  • Gasiorowski, R., Clark, G., Bradstock, K., Hart, D. (2014). Antibody therapy for acute myeloid leukaemia. British Journal of Haematology, 164(4), 481-495. [More Information]
  • Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, J., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia and Lymphoma, 55(5), 1090-1098. [More Information]

2013

  • Hardy, M., Vari, F., Rossetti, T., Hart, D., Prue, R. (2013). A flow cytometry based assay for the enumeration of regulatory T cells in whole blood. Journal of Immunological Methods, 390(1-2), 121-126. [More Information]
  • Shahin, K., Sartor, M., Hart, D., Bradstock, K. (2013). Alterations in Chemokine Receptor CCR5 Expression on Blood Dendritic Cells Correlate With Acute Graft-Versus-Host Disease. Transplantation, 96(8), 753-762. [More Information]
  • Gasiorowski, R., Ju, X., Hart, D., Clark, G. (2013). CD300 molecule regulation of human dendritic cell functions. Immunology Letters, 149(1-2), 93-100. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]

2012

  • Brown, R., Karieshma, K., Favaloro, J., Yang, S., Joy Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012). CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosis. Blood, 120(10), 2055-2063. [More Information]
  • Kassianos, A., Hardy, M., Ju, X., Vijayan, D., Ding, Y., Vulink, A., McDonald, K., Jongbloed, S., Wadley, R., Wells, C., Hart, D., et al (2012). Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli. European Journal of Immunology, 42(6), 1512-1522. [More Information]
  • Wilkinson, R., Woods, K., D'Rozario, R., Prue, R., Vari, F., Hardy, M., Dong, Y., Clements, J., Hart, D., Radford, K. (2012). Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology, Immunotherapy, 61(2), 169-179. [More Information]
  • Li, S., Roberts, S., Plebanski, M., Gouillou, M., Spelman, T., Latour, P., Jackson, D., Brown, L., Sparrow, R., Prince, H., Hart, D., et al (2012). Induction of Multi-Functional T Cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals. PLoS One, 7(8), 1-7. [More Information]

2011

  • Fromm, P., Gottlieb, D., Bradstock, K., Hart, D. (2011). Cellular therapy to treat haematological and other malignancies: progress and pitfalls. Pathology, 43(6), 605-615. [More Information]
  • Freeman, L., Lam, A., Petcu, E., Smith, R., Salajegheh, A., Diamond, P., Zannettino, A., Evdikiou, A., Luff, J., Hart, D., et al (2011). Myeloma-induced alloreactive T cells arising in myeloma infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model. Journal of Immunology, 187(8), 3987-3996. [More Information]
  • Ding, Y., Ju, X., Azlan, M., Hart, D., Clark, G. (2011). Screening of the HLDA9 panel on peripheral blood dendritic cell populations. Immunology Letters, 134(2), 161-166. [More Information]
  • Hart, D. (2011). The delivery of effective therapeutic cancer vaccination. Asian Journal of Andrology, 13(2), 183-184. [More Information]

2010

  • Jones, M., Seldon, T., Smede, M., Linville, A., Chin, D., Barnard, R., Mahler, S., Munster, D., Hart, D., Gray, P., et al (2010). A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. Journal of Immunological Methods, 354(1-Feb), 85-90. [More Information]
  • Gowans, E., Roberts, S., Jones, K., Dinatale, I., Latour, P., Chua, B., Eriksson, E., Chin, R., Li, S., Wall, D., et al (2010). A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. Journal of Hepatology, 53(4), 599-607. [More Information]
  • Jongbloed, S., Kassianos, A., McDonald, K., Clark, G., Ju, X., Angel, C., Chen, C., Dunbar, P., Wadley, R., jeet, V., Hart, D., et al (2010). Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. The Journal of Experimental Medicine, 207(6), 1247-1260. [More Information]
  • Kassianos, A., Jongbloed, S., Hart, D., Radford, K. (2010). Isolation of Human Blood DC Subtypes. Methods in Molecular Biology, 595(2010), 45-54. [More Information]
  • Dean, M., Flower, R., Eisen, D., Minchinton, R., Hart, D., Vuckovic, S. (2010). Mannose-binding lectin deficiency influences innate and antigen-presenting functions of blood myeloid dendritic cells. Immunology, 132(2), 296-305. [More Information]
  • Christensen, M., Turner, B., Sinfield, L., Kollar, K., Cullup, H., Waterhouse, N., Hart, D., Atkinson, K., Rice, A. (2010). Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease. Haematologica: the hematology journal, 95(12), 2102-2110. [More Information]
  • Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., Dalod, M., Grau, V., Hart, D., Leenen, P., Liu, Y., MacPherson, G., Randolph, G., et al (2010). Nomenclature of monocytes and dendritic cells in blood. Blood, 116(16), e74-e80. [More Information]
  • Ju, X., Clark, G., Hart, D. (2010). Review of human DC subtypes. Methods in Molecular Biology, 595, 3-20. [More Information]

2009

  • Wilson, J., Cullup, H., Lourie, R., Sheng, Y., Palkova, A., Radford, K., Dickinson, A., Rice, A., Hart, D., Munster, D. (2009). Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. The Journal of Experimental Medicine, 206(2), 387-398. [More Information]
  • Hardy, M., Kassianos, A., Vulink, A., Wilkinson, R., Jongbloed, S., Hart, D., Radford, K. (2009). NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunology and Cell Biology, 87(8), 606-614. [More Information]
  • Clark, G., Ju, X., Tate, C., Hart, D. (2009). The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends in Immunology, 30(5), 209-217. [More Information]
  • Clark, G., Ju, X., Azlan, M., Tate, C., Ding, Y., Hart, D. (2009). The CD300 molecules regulate monocyte and dendritic cell functions. Immunobiology, 214, 730-736. [More Information]

2008

  • Hart, D., Clark, G., Ju, X., Zenke, M. (2008). Cd300a and Cd300c on Plasmacytoid Dendritic Cells Are down-Regulated by Tlr7 and Tlr9 Ligand Induced Type I Interferon. Biology of Blood and Marrow Transplantation, 14(2), 118-118.
  • Ju, X., Zenke, M., Hart, D., Clark, G. (2008). CD300a/c regulate type I interferon and TNF-(alpha) secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood, 112, 1184-1194. [More Information]
  • Vuckovic, S., Wahid, F., Rice, A., Kato, M., Khalil, D., Rodwell, R., Hart, D. (2008). Compartmentalization of allogeneic T-cell responses in the bone marrow and spleen of humanized NOD/SCID mice containing activated human resident myeloid dendritic cells. Experimental Hematology, 36, 1496-1506. [More Information]
  • Vulink, A., Radford, K., Melief, C., Hart, D. (2008). Dendritic Cells in Cancer Immunotherapy. Advances in Cancer Research, 99, 363-407. [More Information]
  • Vari, F., Munster, D., Hsu, J., Rossetti, T., Mahler, S., Grey, P., Turtle, C., Prue, R., Hart, D. (2008). Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma. British Journal of Haematology, 143(3), 374-377. [More Information]
  • Turner, B., Kambouris, M., Sinfield, L., Lange, J., Burn, A., Lourie, R., Atkinson, K., Hart, D., Munster, D., Rice, A. (2008). Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem-Cell Transplant Determines the Kinetics of Acute Graft-Versus-Host Disease. Transplantation, 86(7), 968-976. [More Information]
  • Hart, D., Vuckovic, S., Alison, R., Kato, M., Khalil, D., Fadilah, S., Rodwell, R. (2008). Resident Human Myeloid Dendritic Cell Activation and Local Allogeneic T Cell Responses in the Bone Marrow of Humanized NOD/SCID Mice. Biology of Blood and Marrow Transplantation, 14(2), 145-145.
  • Liu, X., Hart, D., MacPherson, G., Good, M., Wykes, M. (2008). Soluble CD38 significantly prolongs the lifespan of memory B-cell responses. Immunology, 125, 14-20. [More Information]

2007

  • Lau, J., Sartor, M., Bradstock, K., Vuckovic, S., Munster, D., Hart, D. (2007). Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease. Transplantation, 83(7), 839-846. [More Information]
  • Freeman, J., Vari, F., Hart, D. (2007). Activated CMRF-56 selected blood dendritic cells: A potential anti-myeloma vaccine. Blood, 110(11), 739a-740a.
  • Freeman, J., Vari, F., Hart, D. (2007). CMRF-56 immunoselected blood dendritic cell preparations activated with GM-CSF induce potent antimyeloma cytotoxic T-cell responses. Journal of Immunotherapy, 30(7), 740-748. [More Information]
  • Fadilah, S., Vuckovic, S., Khalil, D., Hart, D. (2007). Cord Blood CD34+ Cells Cultured with FLT3L, Stem Cell Factor, Interleukin-6, and IL-3 Produce CD11c+CD1a-/c Myeloid Dendritic Cells. Stem Cells and Development, 16, 849-855. [More Information]
  • Vuckovic, S., Withers, G., Harris, M., Khalil, D., Gardiner, D., Flesch, I., Tepes, S., Greer, R., Cowley, D., Cotterill, A., Hart, D. (2007). Decreased blood dendritic cell counts in type 1 diabetic children. Clinical Immunology, 123, 281-288. [More Information]
  • Young, J., Merad, M., Hart, D. (2007). Dendritic Cells in Transplantation and Immune-Based Therapies. Biology of Blood and Marrow Transplantation, 13(Supp. 1), 23-32. [More Information]
  • Clark, G., Jamriska, L., Rao, M., Hart, D. (2007). Monocytes immunoselected via the novel monocyte specific molecule, CD300e, differentiate into active migratory dendritic cells. Journal of Immunotherapy, 30(3), 303-311. [More Information]
  • Hart, D., Rao, M., Ju, X., Clark, G. (2007). Novel Human CD4+ T Lymphocyte Subpopulations Defined by CD300a/c Molecule Expression. Blood, 110(11), 682a-682a.
  • Clark, G., Rao, M., Ju, X., Hart, D. (2007). Novel human CD4+ T lymphocyte subpopulations defined by CD300a/c molecule expression. Journal of Leukocyte Biology, 82(5), 1126-1135. [More Information]
  • Hardy, M., Kassianos, A., Wilkinson, R., Vulink, A., Hart, D., Radford, K. (2007). Residual Lymphocytes in GM-CSF and IL-15 Differentiated Monocyte-Derived Dendritic Cells Enables Cytotoxic T Lymphocyte Responses. Blood, 110(11), 302b-302b.
  • Hart, D., Khan, S., d'Aniello, E., MacDonald, K., Kato, M. (2007). Role of Novel C-Type Lectin Receptor DCL-1 in Phagocytes and Dendritic Cells. Blood, 110(11), 713a-714a.
  • Kato, M., Khan, S., d’Aniello, E., McDonald, K., Hart, D. (2007). The Novel Endocytic and Phagocytic C-Type Lectin Receptor DCL-1/CD302 on Macrophages Is Colocalized with F-Actin, Suggesting a Role in Cell Adhesion and Migration. Journal of Immunology, 179, 6052-6063. [More Information]

2006

  • Cullup, H., Wilson, J., Dickinson, A., Hart, D., Munster, D. (2006). Anti-CD83 mediated suppression of alloimmune responses. Immunology and Cell Biology, 84(3), A15-A6.
  • Hsu, A., Kerr, B., Lock, R., Hart, D., Rice, A. (2006). Anti-leukemic CTL generated by RNA loaded cord blood-derived dendritic cells control leukaemia in a NOD-SCID mouse model. Blood, 108(11), 1057a-1057a.
  • Cullup, H., Wilson, J., Rice, A., Dickinson, A., Munster, D., Hart, D. (2006). Antibody targeting of activated dendritic cells prevents AGVHD and preserves T cell immunity. Blood, 108(11), 925a-925a.
  • Radford, K., Turtle, C., Kassianos, A., Hart, D. (2006). CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression. Journal of Immunotherapy, 29(6), 596-605. [More Information]
  • Hart, D., Venter, D. (2006). Dendritic cells in leukemia and lymphoma. Leukemia and lymphoma, 47(4), 572-573. [More Information]
  • Lau, J., Sartor, M., Vuckovic, S., Munster, D., Bradstock, K., Hart, D. (2006). Expression of activation marker, CMRF-44, on blood CD11c(hi) dendritic cells is closely associated with the severity of acute gvhd after allogeneic haematopoietic stem cell transplant. Immunology and Cell Biology, 84(3), A9-A9.
  • Kato, M., McDonald, K., Khan, S., Ross, I., Vuckovic, S., Chen, K., Munster, D., MacDonald, K., Hart, D. (2006). Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. International Immunology, 18(6), 857-869. [More Information]
  • Khan, S., Hsu, R., Jones, A., Ross, I., Hart, D., Kato, M. (2006). IdentiWcation of the dominant translation start site in the attB1 sequence of the pET-DEST42 Gateway vector. Protein Expression and Purification, 49, 102-107. [More Information]
  • Wilson, J., Cullup, H., Rice, A., Hart, D., Munster, D. (2006). In vivo depletion of human activated dendritic cells prevents graft versus host disease in a human-mouse chimeric model. Experimental Hematology, 34(9), 44-44.
  • Modra, C., Jamriska, L., Rao, M., Clark, G., Hart, D. (2006). MMRI-23: A potential role in AML antibody-mediated therapy. Blood, 108(11), 225b-225b.
  • Wilkinson, R., Kassianos, A., Swindle, P., Hart, D., Radford, K. (2006). Numerical and Functional Assessment of Blood Dendritic Cells in Prostate Cancer Patients. The Prostate, 66, 180-192. [More Information]
  • Hsu, A., Kerr, B., Jones, K., Lock, R., Hart, D., Rice, A. (2006). RNA Loading of Leukemic Antigens into Cord Blood-Derived Dendritic Cells for Immunotherapy. Biology of Blood and Marrow Transplantation, 12, 855-867. [More Information]
  • Wahid, F., Rice, A., Khalil, D., Rodwell, R., Hart, D. (2006). Stem cells develop into human blood dendritic cells in humanized NOD/SCID mice. Cytometry Part A, 69A(5), 405-405.
  • Cooper, B., Key, B., Carter, A., Angel, N., Hart, D., Kato, M. (2006). Suppression and overexpression of adenosylhomocysteine hydrolase like protein 1 (AHCYL1) influences zebrafish embryo development - a possible role for AHCYL1 in inositol phospholipid signaling. Journal of Biological Chemistry, 281(11), 22471-22484. [More Information]
  • Collin, M., Hart, D., Jackson, G., Cook, G., Cavet, J., Mackinnon, S., Middleton, P., Dickinson, A. (2006). The fate of human Langerhans cells in hematopoietic stem cell transplantation. The Journal of Experimental Medicine, 203(1), 27-33. [More Information]

2005

  • Wilson, J., Rice, A., Hart, D., Munster, D. (2005). A murine transplantation model of in vivo dendritic cell depletion to attenuate graft versus host disease. Biology of Blood and Marrow Transplantation, 11(2 supp. 1), 43-43.
  • Kato, M., Khan, S., McDonald, K., Hart, D. (2005). A novel C-type lectin receptor DCL-1 (CD302) is a potential endocytic receptor for tumor antigen loading into antigen presenting cells. Blood, 106(11), 628a-628a.
  • Modra, C., Radford, K., Gardiner, D., Hart, D., Clark, G. (2005). An inhibitory molecule involved in myeloid and DC differentiation. Tissue Antigens: immune response genetics, 66(5), 494-494.
  • Hsu, A., Kerr, B., Lock, R., Hart, D., Rice, A. (2005). Assembling the players for evaluation of anti-leukemic CTL activity in NOD-SCID mice. Blood, 106(11), 226b-226b.
  • Turner, B., Christensen, M., Lange, J., Burns, A., Hart, D., Atkinson, K., Munster, D., Rice, A. (2005). Conditioning Intensity and Dendritic Cell (DC) Activation: Implications for GVHD Control Using DC Depleting Antibodies. Blood, 106(11), 870a-870a.
  • Hart, D. (2005). Dendritic cell biology evolves into clinical application. The Lancet, 365(9454), 102-104. [More Information]
  • Field, K., Vuckovic, S., Hart, D. (2005). Dendritic Cells. In Michael T. Lotze and Angus W. Thomson (Eds.), Measuring Immunity, (pp. 290-298). Elsevier.
  • Clark, G., Munster, D., Yusuf, S., Hart, D. (2005). Eighth Leucocyte DiVerentiation Antigen Workshop DC section summary. Cellular Immunology, 236, 21-28. [More Information]
  • McKinlay, A., Radford, K., Gardiner, D., Khalil, D., Field, K., Burnell, F., Hart, D., Vuckovic, S. (2005). Human memory CD4(+) T cells maintained in the absence of antigen develop regulatory T cells capable of suppressing antibody responses. 66(5), 581-582.
  • Radford, K., Turtle, C., Kassianos, A., Vuckovic, S., Gardiner, D., Khalil, D., Taylor, K., Wright, S., Gill, D., Hart, D. (2005). Immunoselection of Functional CMRF-56+ Blood Dendritic Cells from Multiple Myeloma Patients for Immunotherapy. Journal of Immunotherapy, 28(4), 322-331. [More Information]
  • Collin, M., Munster, D., Clark, G., Wang, X., Dickinson, A., Hart, D. (2005). In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of Graft-versus-host disease. Transplantation, 79(6), 722-725. [More Information]
  • Dean, M., Minchinton, R., Vuckovic, S., Hart, D. (2005). Mannose binding lectin facilitates aggregation between cells of innate and adaptive immunity and pathogen recognition. Tissue Antigens: immune response genetics, 66(5), 396-396.
  • Wilson, J., Rice, A., Hart, D., Munster, D. (2005). Prevention of graft versus host disease by antibody mediated depletion of activated dendritic cells. Biology of Blood and Marrow Transplantation, 11(2), 43-43. [More Information]
  • Hardy, M., Kassianos, A., Clark, G., Hart, D., Radford, K. (2005). Production of IL-2, IL-12, and IL-10 by human blood myeloid dendritic cells. Tissue Antigens: immune response genetics, 66(5), 437-437.
  • Vuckovic, S., Khalil, D., Angel, N., Jahnsen, F., Hamilton, I., Boyce, A., Hock, B., Hart, D. (2005). The CMRF58 antibody recognizes a subset of CD123hi dendritic cells in allergen-challenged mucosa. Journal of Leukocyte Biology, 77(3), 344-351. [More Information]
  • Khan, S., Hsu, R., Hart, D., Kato, M. (2005). The use of the C type lectins DEC-205 (CD205) and DCLA (CD302) to load tumor-associated antigens into dendritic cells. Tissue and Cell, 66(5), 462-463.
  • Radford, K., Vari, F., Hart, D. (2005). Vaccine strategies to treat lymphoproliferative disorders. Pathology, 37(6), 534-550. [More Information]

2004

  • Turtle, C., Brown, R., Joshua, D., Hart, D. (2004). DC in multiple myeloma immunotherapy. Cytotherapy, 6(2), 128-137.
  • A, R., Jones, K., Hart, D. (2004). DC preparations for therapy. Cytotherapy, 6(2), 99-104.
  • Turtle, C., Hart, D. (2004). Dendritic cells in tumor immunology and immunotherapy. Current Drug Targets, 5(1), 17-39.
  • Hsu, A., Kerr, B., Allan, C., Turtle, C., Hart, D., Rice, A. (2004). Effective RNA loading of CD34(+) derived dendritic cells for adoptive immunotherapy. Biology of Blood and Marrow Transplantation, 10(2), 47-47.
  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β�? In Patients With Myeloma. British Journal of Haematology, 125(2), 743-748.
  • Hart, D. (2004). In Focus - Introduction. Cytotherapy, 6(2), 87.
  • Sénéchal, B., Boruchov, A., Reagan, J., Hart, D., Young, J. (2004). Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood, 103(11), 4207-4215.
  • Vari, F., Hart, D. (2004). Loading DCs with Ag. Cytotherapy, 6(2), 111-121.
  • Vuckovic, S., Gardiner, D., Field, K., Chapman, G., Khalil, D., Gill, D., Marlton, P., Taylor, K., Wright, S., Pinzon-Charry, A., Hart, D., et al (2004). Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. Journal of Immunological Methods, 284, 73-87.
  • Turtle, C., Radford, K., Allan, C., Kassianos, A., Kato, M., Vuckovic, S., MacDonald, K., Lopez, J., Jackson, D., Wright, S., Hart, D., et al (2004). RNA-loading of CMRF-56 positive blood dendritic cells is a promising strategy for multiple myeloma immunotherapy. Biology of Blood and Marrow Transplantation, 10(2), 71-71.
  • Allan, C., Turtle, C., Mainwaring, P., Pyke, C., Hart, D. (2004). The immune response to breast cancer, and the case for DC immunotherapy. Cytotherapy, 6(2), 154-163.
  • Wilson, J., Rice, A., Hart, D., Munster, D. (2004). Therapeutic antibody mediated depletion of activated dendritic cells and the prevention of graft versus host disease. Biology of Blood and Marrow Transplantation, 10(2), 48-48.

2003

  • Hart, D., Khan, S., McDonald, K., O’Neill, B., Gonzalez, N., Kato, M. (2003). A novel C-type lectin receptor DCL-1 is a potential Endocytic receptor expressed on phagocytes. Blood, 102(11), 523a-523a.
  • Koppi, T., Munster, D., Brown, L., MacDonald, K., Hart, D. (2003). CMRF-44 antibody-mediated depletion of activated human dendridic cells: a potential means for improving allograft survival. Transplantation, 75(10), 1723-1730.
  • Barrow, L., Brown, R., Murray, A., Sze, D., POPE, B., Gibson, J., Hart, D., Joshua, D. (2003). CMRF44+ Dendritic Cells from Peripheral Blood Stem Cell Harvests of Patients with Myeloma as Potential Cellular Vectors for Idiotype Vaccination. Leukemia and lymphoma, 44(12), 2117-2122.
  • MacDonald, K., Rowe, V., Filippich, C., Thomas, R., Clouston, A., Welpy, J., Hart, D., Ferrara, J., Hill, G. (2003). Donor pretreatment with progenipoietin-1 is superior to granulocyte colony–stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood, 101(5), 2033-2042.
  • Kato, M., Khan, S., Gonzalez, N., O’Neill, B., McDonald, K., Cooper, B., Angel, N., Hart, D. (2003). Hodgkin’s Lymphoma Cell Lines Express a Fusion Protein Encoded by Intergenically Spliced mRNA for the Multilectin Receptor DEC-205 (CD205) and a Novel C-type Lectin Receptor DCL-1*. Journal of Biological Chemistry, 278(36), 34035-34041.
  • Turtle, C., Radford, K., Allan, C., Kato, M., Hart, D. (2003). RNA-loading of CMRF-56 positive blood dendritic cells is a promising strategy for multiple myeloma immunotherapy. Blood, 102(11), 391b-391b.
  • Lopez, J., Bioley, G., Turtle, C., Pinzon-Charry, A., Ho, C., Vuckovic, S., Crosbie, G., Jackson, D., Gilleece, M., Munster, D., Hart, D. (2003). Single step enrichment of blood dendritic cells by positive immunoselection. Journal of Immunological Methods, 274, 47-61.

To update your profile click here. For support on your academic profile contact .